Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Avelox, Similar Antibiotics Face European Restrictions Due to Liver Damage

Jul 31, 2008 | Parker Waichman LLP

Moxifloxicin, a fluoroquinolone antibiotic sold as Avelox by Bayer, is being subjected to new warnings and restrictions by the European Medicines Agency (EMA) because of its association with adverse liver reactions.  

Moxifloxacin is used to treat respiratory infections, including acute sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia, as well as skin and skin structure infections. Moxifloxacin is also used for the treatment of complicated intra-abdominal infections, such as those seen in hospitals.  It has also been used as a second line treatment for tuberculosis.

In February 2008, Bayer issued a "Dear Healthcare Provider" letter to doctors in Europe warning that Avelox (moxifloxacin) had caused incidents of severe liver and skin side effects in patients.  Bayer has included the additional warnings in the packaging of Avelox products since the previous autumn, after some incidents of severe side effects were monitored.

Today, the European Medicines Agency (EMEA) announced it had completed a review of new data on the safety of oral formulations  of Avalox and other moxifloxacin-containing medicines. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia continue to outweigh their risks. However, due to safety concerns, mainly related to an increased risk of adverse hepatic reactions, CHMP recommended restricting their use to the treatment of these conditions when other antibiotics cannot be used or have failed. CHMP also recommended that the warnings of oral moxifloxacin-containing medicines be strengthened concerning the risk of diarrhea, heart failure in women and older patients, severe skin reactions and fatal liver injury.

The CHMP opinion will now be forwarded to the European Commission to apply to all oral moxifloxacin-containing medicines authorized in the European Union.


Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo